Interesting KURA Put And Call Options For July 2026

Kura Oncology (KURA) is trading at $11.73 and Stock Options Channel highlights two option strategies: selling a put at the $11.00 strike with a $0.80 bid (puts buyer receives premium) equating to a $10.20 effective cost basis and ~6% below current price, with a 69% probability of expiring worthless and a 7.27% one-period YieldBoost (11.35% annualized). On the call side, a $14.00 call bid of $1.80 sold as a covered call would cap upside at $14 but would yield a 34.70% total return to July 2026 if called (19% OTM), a 15.35% immediate premium boost (23.94% annualized), and has a 43% chance of expiring worthless; implied volatilities are ~95–96% vs. trailing 12-month volatility of 58%.

Analysis

Market structure: Elevated implied volatility (95–96% vs realized 58%) and a rich options market create clear winners — option premium sellers and market-makers collecting elevated theta — and losers if a binary clinical or financing event occurs (option buyers). The put ($11, $0.80) and call ($14, $1.80) prices imply an efficient market view that prices idiosyncratic biotech risk into liquid option strikes over an ~8‑month Jul‑2026 horizon.

Risk assessment: Tail risks are classic biotech binaries — negative trial/FDA outcomes or a dilutive secondary offering — which would likely drop KURA >40% and spike IV further; low-probability regulatory shocks could turn the 69%/43% expiry odds meaningless. Immediate risk (days) is IV gyration and theta; short term (weeks–months) is news flow and potential dilution; long term (quarters) is runway and data readouts that determine survival or acquisition value.

Trade implications: For income-seeking exposure, shorting the $11 Jul‑26 put yields a covered-entry cost basis of $10.20 and an ~11.4% annualized carry if held to expiry, but sellers should size small (1–3% portfolio) and hedge tail risk with a protective lower strike. Alternatives: sell covered $14 calls on existing stock to lock 34.7% upside to $14, or implement defined‑risk put spreads (sell $11 / buy $7.50 Jul‑26) to cap assignment loss.

Contrarian angles: The market may be overstating downside — IV premium exceeds realized by ~38 percentage points — creating an edge for disciplined premium sellers and defined-risk spreads, provided catalysts are tracked. Conversely, if management files a financing or a negative readout, volatility can blow out further; position sizing and strict liquidity/cash-for-assignment rules are the critical anti-fragility measures.

Key Decisions for Investors

• Sell-to-open Jul‑2026 KURA $11 puts size 1–3% of portfolio (collect $0.80, effective basis $10.20). Close or buy back if implied vol compresses below 70% or stock rises above $13.50 (lock 30%+ unrealized gain on option), and cap max assignment exposure to available cash.
• If already long KURA, sell-to-open Jul‑2026 $14 covered calls on 50–100% of position to realize 34.7% upside-to-exercise (collect $1.80). If unwilling to be called away, roll calls only if premium for next 6–9 months ≥10% of share value.
• Use defined‑risk put spread instead of naked puts: sell Jul‑2026 $11 put and buy Jul‑2026 $7.50 put to limit downside; size 1–2% and treat worst‑case loss as buy price of stock at $11 minus spread protection.
• Implement a relative-value hedge: pair long KURA equity position (1–2% portfolio) with a 0.5–1.0x notional short in XBI (or IBB) to isolate KURA idiosyncratic moves; unwind hedge if KURA IV/realized convergence falls below 10 percentage points.